Nagla Abdel Karim, MD (IMAGE)
Caption
Dr. Nagla Abdel Karim, of the Inova Schar Cancer Institute, led the SWOG S1929 phase 2 trial, which found that among patients with extensive stage small-cell lung cancer that was positive for SLFN11 expression, those who received atezolizumab plus talazoparib had significantly longer progression-free survival times than those who received atezolizumab alone.
Credit
Inova
Usage Restrictions
Credit Inova
License
Original content